Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population

被引:21
|
作者
Lee, Hokyou [1 ]
Lim, Tae Seop [2 ,3 ]
Kim, Seung Up [2 ,4 ]
Kim, Hyeon Chang [1 ]
机构
[1] Yonsei Univ, Dept Prevent Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[3] Yongin Severance Hosp, Dept Internal Med, Yongin, South Korea
[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
关键词
Metabolic dysfunction-associated fatty liver disease; Non-alcoholic fatty liver disease; Fatty liver; Cardiovascular disease; Subtype; DIABETES-MELLITUS; RISK; OBESITY;
D O I
10.1007/s12072-022-10407-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims The new metabolic dysfunction-associated fatty liver disease (MAFLD) criteria include the following three distinct subtypes: MAFLD with diabetes mellitus (DM), overweight/obese (OW), or lean/normal weight with metabolic dysfunction. We investigated whether long-term cardiovascular disease outcomes differ across the MAFLD subtypes. Methods From a nationwide health screening database, we included 8,412,730 participants (48.6% males) aged 40-64 years, free of cardiovascular disease history, between 2009 and 2010. Participants were categorized into non-MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. The primary outcome was a composite cardiovascular disease event, including myocardial infarction, ischemic stroke, heart failure, or cardiovascular disease-related death. The presence of advanced liver fibrosis was estimated using a BARD score >= 2. Results Among the study participants, 3,087,640 (36.7%) had MAFLD, among which 2,424,086 (78.5%), 170,761 (5.5%), and 492,793 (16.0%) had OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Over a median follow-up period of 10.0 years, 169,433 new cardiovascular disease events occurred. With the non-MAFLD group as reference, multivariable-adjusted hazard ratios (95% confidence intervals) for cardiovascular disease events were 1.16 (1.15-1.18), 1.23 (1.20-1.27), and 1.82 (1.80-1.85) in the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively. Participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular disease risk than those with OW-MAFLD, irrespective of metabolic abnormalities or comorbidities. The presence of advanced liver fibrosis was significantly associated with a higher cardiovascular disease risk in each MAFLD subtype. Conclusion Long-term cardiovascular disease outcomes differed across the MAFLD subtypes. Further studies are required to investigate whether preventive or therapeutic interventions should be optimized according to the MAFLD subtypes.
引用
收藏
页码:1308 / 1317
页数:10
相关论文
共 50 条
  • [1] Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population
    Hokyou Lee
    Tae Seop Lim
    Seung Up Kim
    Hyeon Chang Kim
    [J]. Hepatology International, 2022, 16 : 1308 - 1317
  • [2] Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease
    Moon, Joon Ho
    Kim, Won
    Koo, Bo Kyung
    Cho, Nam H.
    [J]. GUT AND LIVER, 2022, 16 (03) : 433 - 442
  • [3] Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population
    Yang, Sheng
    Cheng, Jiawen
    Zhang, Rui
    Sun, Huiwen
    Zhang, Hui
    Lyu, Sali
    Duan, Weiwei
    [J]. HEPATOLOGY RESEARCH, 2022, 52 (02) : 176 - 186
  • [4] The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
    Ziyan Feng
    Fanrong Zhao
    Ziyao Wang
    Xinyi Tang
    Yan Xie
    Li Qiu
    [J]. BMC Gastroenterology, 24
  • [5] The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
    Feng, Ziyan
    Zhao, Fanrong
    Wang, Ziyao
    Tang, Xinyi
    Xie, Yan
    Qiu, Li
    [J]. BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [6] Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese
    Yang, Jialu
    Luo, Shiyun
    Li, Rui
    Ju, Jingmeng
    Zhang, Zhuoyu
    Shen, Jichuan
    Sun, Minying
    Fan, Jiahua
    Xia, Min
    Zhu, Wei
    Liu, Yan
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (10): : 2874 - 2882
  • [7] Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Lim, Tae Seop
    Chun, Ho Soo
    Kim, Soon Sun
    Kim, Ja Kyung
    Lee, Minjong
    Cho, Hyo Jung
    Kim, Seung Up
    Cheong, Jae Youn
    [J]. GUT AND LIVER, 2023, 17 (04) : 610 - 619
  • [8] FIBROTIC BURDEN IN LIVER DIFFERS ACROSS METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE SUBTYPES
    Lim, Tae Seop
    Chun, Ho Soo
    Kim, Soon Sun
    Kim, Ja Kyung
    Lee, Minjong
    Cho, Hyo Jung
    Kim, Seung Up
    Cheong, Jaeyoun
    [J]. HEPATOLOGY, 2022, 76 : S657 - S657
  • [9] Education and income are associated with long-term outcome in the metabolic dysfunction-associated steatotic liver disease population
    Zhao, Qianwen
    Deng, Yunlei
    [J]. GERIATRICS & GERONTOLOGY INTERNATIONAL, 2023, 23 (12) : 975 - 976
  • [10] Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease
    Huang, Hangkai
    Guo, Yanjun
    Liu, Zhening
    Zeng, Yan
    Chen, Yishu
    Xu, Chengfu
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (08): : E3295 - E3303